Figure 1:Most frequently reported
IMP-related AEs (>5%) for subjects treated with 12 SQ-Bet
(pooled population) by severity.Figure 2: Median
onset and duration of most frequent IMP-related treatment emergent AEs
(≥1%) for subjects treated with 12 SQ-Bet, pooled population. Figure 3A: IMP-related AEs in adults and adolescents with
and without asthma (pooled population) by treatment group. Figure 3B: IMP-related AEs by severity in adults and
adolescents with and without asthma for subjects treated with 12
SQ-Bet.Figure 4: Forest plot of hazard ratios of first moderate
or severe IMP-related AE in various subgroups.